Adaptive, Gilead, Juno, aTyr & More
Summary
It just happened that two executives who spoke at Xconomy’s annual Seattle biotech forum Wednesday represented local companies, Adaptive Biotechnologies and Juno Therapeutics, in this week’s news.More than half of the cash is intended to advance aTyr’s development of lead drug Resolaris, a treatment for facioscapulohumeral muscular dystrophy (FSHD), a genetically based degeneration of muscles in the face, shoulder blades, and upper arms.—Tobira (NASDAQ: TBRA) of South San Francisco, CA, finalized a reverse merger to go public, using the shell of Regado Biosciences, whose massive Phase 3 trial for an anticoagulant drug failed last summer.—Redwood City, CA-based AcelRx Pharmaceuticals (NASDAQ: ACRX) on Monday said the FDA has reinforced its view that the company needs to conduct another late-stage clinical trial for its pain treatment Zalviso (sufentanil).—The recent unexpected departures of chairman and CEO Alex Lukianov and COO Keith Valentine from San Diego’s NuVasive (NASDAQ: NUVA) didn’t hold back earnings or revenue at the spinal implant maker.
Classifications
AskAI Classifications
LabelsLinked Companies
